 Efficacy toxicity sodium stibogluconate mucosal leishmaniasis OBJECTIVE efficacy toxicity World Health Organization WHO treatment mucosal leishmaniasis antimony mg/kg body weight day days DESIGN Open trial follow-up SETTING Inpatient unit regional referral hospital developing country PATIENTS Twenty-nine consecutive eligible patients culture-confirmed infection mucosa Leishmania species healthy patients disease nasal mucosa patients severe disease oropharynx nasal mucosa INTERVENTION Antimony mg/kg body day days Patients antimony form sodium stibogluconate MEASUREMENTS MAIN RESULTS Initial results therapy lesions lesions culture-negative parasites patients complete clinical parasitologic cure lesions follow-up examinations lesions new lesions patients clinical cure lesions patients mild disease patients severe disease Side effects treatment regimen T-wave inversion electrocardiogram patients abnormal liver function tests patients musculoskeletal pain patients side effects week therapy CONCLUSIONS recommended treatment mucosal leishmaniasis ineffective patients severe disease acceptable toxicity regimen courses therapy antimony trials antileishmanial agents antimony initial therapy disease